ArticleJournal of medical biochemistry2026
Combined detection of CXCR7 and CXCL12 for diagnosing acute myocardial infarction and predicting post-percutaneous coronary intervention major adverse cardiovascular events.
Article in Journal of medical biochemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: To explore the diagnostic utility of combined CXCR7 and CXCL12 testing in acute myocardial infarction (AMI) and its predictive value for post-percutaneous coronary intervention (PCI) major adverse cardiovascular events (MACE). Methods: This study enrolled 164 AMI patients and 54 healthy controls from January to June 2024. All patients received standardized PCI and were followed for 12 months. Serum CXCR7 and CXCL12 concentrations were determined via enzyme-linked immunosorbent assay (ELISA), while NT-proBNP was quantified with an automated biochemical analyzer. Comparative analyses of biomarker levels between groups were conducted, along with receiver operating characteristic (ROC) curve analysis for combined diagnostic performance. Dynamic changes in CXCR7/CXCL12 were also assessed in relation to postoperative MACE. Results: Pre-treatment concentrations of CXCR7 and CXCL12 were markedly higher in the AMI group relative to controls. The combined detection achieved an AUC value of 0.812 for diagnosing AMI, superior to individual indicators (P< 0.05). Both markers decreased significantly following PCI (P< 0.05). Those who developed MACE exhibited higher post-treatment CXCR7 and CXCL12 levels compared to non-MACE cases; their combined AUC reached 0.806 for predicting post-PCI MACE (P< 0.05). While NT-proBNP demonstrated strong diagnostic accuracy for AMI (AUC = 0.893), it failed to predict post-PCI MACE (P> 0.05). This discrepancy may reflect NT-proBNP's primary association with acute myocardial injury rather than chronic microvascular dysfunction or endothelial repair processes implicated in MACE. Conclusions: The favorable diagnostic performance of CXCR7 and CXCL12 for AMI and post-PCI MACE suggests their potential as a novel protocol for the clinical assessment of AMI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.